Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease
← catalyst calendarNCT05659901 · readout ≤ 955 d
Sponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
32estimated
Sites
9
Countries
France, Germany, Israel +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-03 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pelizaeus-Merzbacher Disease
Primary outcomes
what the primary-completion date above is the date OFAssess Longitudinal Changes in Fluid Biomarkers
measured Up to 26 months
Assess Longitudinal Changes in Neuroimaging Parameters
measured Up to 26 months
Assess longitudinal changes in performance on clinical, and patient and caregiver-reported outcome assessments
measured Up to 26 months
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed